Humanwell Healthcare's subsidiary has obtained acceptance of the application for listing approval for injection-grade Metoprolol hydrochloride.
ST Human Luck (600079.SH) announced that its controlling subsidiary Yichang Human Luck Pharmaceutical Co., Ltd. has recently received the "Acceptance Notification Letter" for the application for the registration and approval of the injection of Landiolol Hydrochloride issued by the National Medical Products Administration.
Humanwell Healthcare (600079.SH) announced that its holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has recently received the "Notice of Acceptance" of the drug registration and market approval application for the injection of metoprolol hydrochloride issued by the National Medical Products Administration.
Metoprolol hydrochloride for injection is a selective 1 receptor blocker, clinically used for: 1. Emergency treatment of the following rapid arrhythmias that occur during surgery: atrial fibrillation, atrial flutter, sinus tachycardia; 2. Emergency treatment of rapid arrhythmias that occur during dynamic monitoring of the circulatory system after surgery: atrial fibrillation, atrial flutter, sinus tachycardia; 3. Treatment of rapid arrhythmias in patients with heart failure: atrial fibrillation, atrial flutter.
Related Articles
HUABAO INTL (00336) announced on June 3 that it repurchased 550,000 shares for HK$2.057 million.
On June 3rd, CHINA STARCH (03838) spent 264,300 Hong Kong dollars to repurchase 1.57 million shares.
LX TECHNOLOGY (02436) spent HK$134,500 to repurchase 5,400 shares on June 3rd.
HUABAO INTL (00336) announced on June 3 that it repurchased 550,000 shares for HK$2.057 million.
On June 3rd, CHINA STARCH (03838) spent 264,300 Hong Kong dollars to repurchase 1.57 million shares.
LX TECHNOLOGY (02436) spent HK$134,500 to repurchase 5,400 shares on June 3rd.
